Skip to main content
. 2011 Nov 29;26(12):1563–1568. doi: 10.3346/jkms.2011.26.12.1563

Fig. 3.

Fig. 3

Effect of sorafenib/EKB-569 co-treatment on the EGFR-targeted resistant SNU-475 cell line. SNU-475 cells were treated with sorafenib alone, EKB-569 alone, or sorafenib plus EKB-569 at the indicated concentrations, for 72 hr. Cellular viability was measured using the CCK-8 assay.